Orphan drug legislation: lessons for neglected tropical diseases
Open Access
- 24 April 2008
- journal article
- research article
- Published by Wiley in The International Journal of Health Planning and Management
- Vol. 24 (1), 27-42
- https://doi.org/10.1002/hpm.930
Abstract
In the last 20 years, orphan drug legislation (ODL) has been adopted in several countries around the world (USA, Japan, Australia, and the European Union) and has successfully promoted R&D investments to develop new pharmaceutical products for the treatment of rare diseases. Without these incentives, many life-saving new drugs would have not been developed and produced. For economic reasons, the development of medicines for the treatment of diseases prevalent in the developing world (or tropical diseases) is lagging behind. Among several factors, the low average per-capita income makes pharmaceutical markets in developing countries appear relatively unprofitable and therefore unattractive for R&D-oriented companies. The case of ODL may offer some useful insights and perspectives for the fight against neglected tropical diseases. First, the measures used in ODL may also be effective in boosting R&D for neglected tropical diseases, if appropriately adapted to this market. Second, small-sized companies, which have played a successful role in the development of orphan drugs for rare diseases, may also represent a good business strategy for the case of tropical diseases. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Adopting Orphan Drugs — Two Dozen Years of Treating Rare DiseasesNew England Journal of Medicine, 2006
- Industry funding of the FDA: effects of PDUFA on approval times and withdrawal ratesNature Reviews Drug Discovery, 2005
- Are novel drugs more risky for patients than less novel drugs?Journal of Health Economics, 2004
- Engaging biotechnology companies in the development of innovative solutions for diseases of povertyNature Reviews Drug Discovery, 2004
- Pharmaceuticals and the Developing WorldJournal of Economic Perspectives, 2002
- Drug development for neglected diseases: a deficient market and a public-health policy failureThe Lancet, 2002
- The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTOJournal of International Economic Law, 2002
- The Global Drug GapScience, 2000
- Success rates for new drugs entering clinical testing in the United StatesCancer Cell, 1995